Rapt Therapeutics

Founded 2015 · CIK 0001673772 · Biotech · Acquired

Oral small molecule CCR4 antagonist

rapttx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$303M
5 Form D · Jan 2025
21 months since last filing
Contracts
—
No federal contracts on record
Patents
40
12 granted · 28 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$50,000,000
Private capital raisedForm D · SEC$29,927,851
Private capital raisedForm D · SEC$22,634,798
Private capital raisedForm D · SEC$50,000,000
Private capital raisedForm D · SEC$149,984,200
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1634MANHATTAN BIOSOLUTIONS, LLC——
1635Find Genomics Inc.——
1636Amplifier Therapeutics——
1637Rapt Therapeutics—$303M
1638SAPPHIRE BIOTECH, INC.——
1639Atalanta Therapeutics——
1640Aera Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 17 related persons
  • Dirk BrockstedtExecutive Officer
  • Michael GiordanoDirector
  • David GoeddelDirector
  • Mary Ann GrayDirector
  • Eric HallExecutive Officer
  • Rekha HemrajaniExecutive Officer
  • William HoExecutive Officer
  • Paul KassnerExecutive Officer
  • Linda KozickDirector
  • Tim LinExecutive Officer
  • Lori Lyons-WilliamsDirector
  • William RieflinDirector
  • Wendye RobbinsDirector
  • Beth SeidenbergDirector
  • Brian WongDirector · Executive Officer
  • David WustrowExecutive Officer
  • Rodney YoungExecutive Officer

Patents

USPTO · 12 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.